Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

NCT07772960 · Not yet recruiting

Last updated 2026-08-27

This clinical trial is testing different doses of semaglutide in adults with alcohol use disorder and obesity to see how it affects alcohol consumption, cravings, and stress hormones.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind study

Participants 90 people Planned (estimated).

Who can join Ages 18–68 · all sexes

Timeline Started 2026-10 · est. completion 2031-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07772960 ↗

Description as written by the study sponsor.

This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.

Treatments tested

Placebo Other

Placebo - administered one weekly for 20 weeks
Semaglutide 1.0 mg Drug

Semaglutide 1.0 mg low dose
Semaglutide 2.0 mg Drug

Semaglutide 2.0 mg high dose

Main thing measured	Alcohol use days
Sponsor	Yale University
Conditions studied	Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07772960 ↗